Mark T.A. Donoghue

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• The Genomic Landscape of <i>MYC</i> , <i>MYCL</i> , and <i>MYCN</i> Amplified Solid Tumors

  Clinical Cancer Research · 2026-06-24

• Supplemental Figures from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

  2026-06-17

• Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

  2026-06-17

• Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

  2026-06-17

• Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

  2026-06-17

• Clinicogenomic analysis of <i>EGFR</i> -mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

  Science Translational Medicine · 2026-06-17

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-03-26 · 2 citations

• Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

  Nature Medicine · 2026-03-25 · 3 citations

• Abstract A050: Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRASG12C inhibitor sotorasib in NSCLC

  Cancer Research · 2026-03-05

• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

  Nature · 2026-03-04 · 4 citations

• Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer

  JCO Precision Oncology · 2026-03-01

• Abstract PS1-11-08: Integrative modeling of multimodal real-world data for improved risk stratification of first-line CDK4/6 inhibitor outcomes in patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer

  Clinical Cancer Research · 2026-02-17

• Dual pancreatic carcinomas: clonally related or independent primaries?

  npj Precision Oncology · 2026-02-07

• Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

  Clinical Cancer Research · 2026-02-02 · 1 citations

• Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

  2025-11-25